News | Structural Heart Occluders | August 08, 2016

AAN: PFO Closure Not Recommended for People with Heart Defect and Stroke

Updated American Academy of Neurology recommendation cites limited evidence, availability of PFO closure devices as method to prevent second stroke

PFO closure, patent foramen ovale, AAN recommendation, American Academy of Neurology, stroke patients

August 8, 2016 — Updated recommendations from the American Academy of Neurology (AAN) states that catheter-based closure should not be routinely recommended for people who have had a stroke and also have a heart defect called a patent foramen ovale (PFO), a channel between the top two chambers in the heart. The practice advisory, which updates a previous AAN guideline, was published in the July 27, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.

To develop the advisory, researchers reviewed all available scientific studies on people with PFO who also had an ischemic stroke, which is a stroke caused by a blood clot, or a transient ischemic attack, which is an episode of temporary stroke symptoms.

“Compared with other ways to prevent a second stroke, such as medications to reduce blood clots, the devices used to close a patent foramen ovale have limited evidence to support their use,” said practice advisory author Steven R. Messé, M.D., with the Perelman School of Medicine at the University of Pennsylvania in Philadelphia and a Fellow of the American Academy of Neurology. “It’s still uncertain how effective these devices are in reducing stroke risk, and the procedure is associated with uncommon but potentially serious complications.”

Read article on how transcatheter structural heart repair is becoming mainstream in the cath lab.

In addition, Messé noted that the devices used for PFO closure are not available for routine use in the United States, so the procedure must be done off-label with a device approved for treating a similar heart defect or with another device that does not have strong evidence regarding its use. At the time of publication, the U.S. Food and Drug Administration is currently reviewing the one device that has the best evidence regarding closure.

Read article on FDA panel's recommendation of the St. Jude Amplatzer PFO Occluder System to prevent recurrent ischemic stroke in certain patients.

“People should know that having a PFO is common — one in four people have one — and the risk of having a second stroke is low,” Messé said.

When the AAN developed the earlier guideline on this topic in 2004, not enough evidence was available to make a recommendation on whether closing a PFO was effective in reducing stroke risk.

The advisory also recommends that aspirin or other antiplatelet drugs be used to prevent blood clots instead of anticoagulant drugs such as warfarin and heparin, also known as blood thinners, unless there is another reason to use blood thinners, such as a person with a history of blood clots in the legs or lungs.

The practice advisory was supported by the American Academy of Neurology.

For more information: www.neurology.org

Related Content

Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart| September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Overlay Init